ALK fusion variants could influence NSCLC crizotinib response
In non-small-cell lung cancer patients with anaplastic lymphoma kinase rearrangement treated with crizotinib, progression-free survival varies according to the ALK fusion variant.
Source: MedWire News - Category: Consumer Health News Tags: Non-small-cell lung cancer Source Type: news
More News: Cancer | Cancer & Oncology | Health | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer